Cost‐utility analysis of semaglutide for type 2 diabetes after its addition to the National Medical Insurance System in China
Authors' conclusion
After its addition to the National Medical Insurance System in China, SEMA is expected to be a cost-effective choice compared with DULA for patients with type 2 diabetes with inadequately controlled from the cost-utility analysis. However, there is still scope to reduce the annual cost of SEMA further.
Study context
- Population
- Patients with inadequately controlled T2D; baseline characteristics and efficacy from high-dose comparison in SUSTAIN-7 trial
- Comparison
- Semaglutide vs dulaglutide
- Outcome
- Long-term cost-effectiveness (incremental cost-utility ratio)
- Follow-up
- Lifetime
Methodological detailsUKPDS OM2 model, health care provider perspective (China), lifetime horizon, binary search, sensitivity analyses
- UKPDS OM2 model
- Health care provider perspective (China)
- Lifetime horizon
- Binary search
- Sensitivity analyses
Main finding
As reported in the abstract
Cost-utility, SEMA vs DULA
Mean difference in quality-adjusted life years (QALYs)
0.04 QALYs
Semaglutide (SEMA)
Mean difference in costs
1132.29 $
SEMA
- Incremental cost-utility ratio
- $26 957.44/QALY
Further findings
Sensitivity analyses
- Discount rate made the greatest contribution to the incremental cost-utility ratio
Binary search for further SEMA price reduction (dulaglutide (DULA) as reference)
- Scope to reduce SEMA cost further to be cost-effective
- ≈6.83%
Original publication
Cost‐utility analysis of semaglutide for type 2 diabetes after its addition to the National Medical Insurance System in China. Diabetes Obes Metab. Published 23 October 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →